| Literature DB >> 20527970 |
Fabrizio Micheli1, Paolo Cavanni, Daniele Andreotti, Roberto Arban, Roberto Benedetti, Barbara Bertani, Michela Bettati, Letizia Bettelini, Giorgio Bonanomi, Simone Braggio, Renzo Carletti, Anna Checchia, Mauro Corsi, Elettra Fazzolari, Stefano Fontana, Carla Marchioro, Emilio Merlo-Pich, Michele Negri, Beatrice Oliosi, Emiliangelo Ratti, Kevin D Read, Maja Roscic, Ilaria Sartori, Simone Spada, Giovanna Tedesco, Luca Tarsi, Silvia Terreni, Filippo Visentini, Alessandro Zocchi, Laura Zonzini, Romano Di Fabio.
Abstract
A pharmacophore model for triple reuptake inhibitors and the new class of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes were recently reported. Further investigation in this area led to the identification of a new series of potent and selective triple reuptake inhibitors endowed with good developability characteristics. Excellent bioavailability and brain penetration are associated with this series of 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptanes together with high in vitro potency and selectivity at SERT, NET, and DAT. In vivo microdialysis experiments in different animal models and receptor occupancy studies in rat confirmed that derivative 17 showed an appropriate profile to guarantee further progression of the compound.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20527970 DOI： 10.1021/jm100481d
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446